nach oben

Journal of Endocrinological Investigation

Erschienen in:

08.11.2023 | Brief Report

Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review

verfasst von: D. Zúñiga, M. A. M. Stumpf, A. L. S. Monteiro, A. Glezer

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the effect of letrozole, an aromatase inhibitor (AI), in patients with resistant prolactinoma that presented an increase in serum prolactin (PRL) levels during testosterone replacement therapy (TRT).

Methods

A retrospective cohort study in a single tertiary care center. From March 2012 to July 2023, 53 male patients over 18 years with prolactinoma were followed in our Neuroendocrine Unit. Of those, 90.6% presented macroadenomas, 41% of them were resistant to cabergoline and 25% presented persistent hypogonadism to whom TRT was indicated. Among them, five presented a significant increase in PRL levels and AI was initiated. All five patients had resistant prolactinomas. One of them was excluded due to tumor aggressiveness and concomitant use of temozolomide during AI therapy.

Results

Four patients were included in the analysis, with a mean age of 28.5 (± 7.5) years, median prolactin of 1060 (600 to 6700) ng/mL and median of the largest tumor diameter of 3.6 (1.5 to 5) cm at the time of prolactinoma diagnosis. On TRT, all presented an increase in serum PRL levels (231 to 396%), with a subsequent decrease (61 to 93%) after adding AI. During AI treatment for a median time of 60.5 (21 to 120) months, tumor shrinkage was observed in two cases (-8 and -3 mm in the maximum diameter) and tumor stability in the other two. No major side effects occurred and AI was well tolerated.

Conclusion

AI might be an option for men with resistant prolactinoma who have an increase in PRL levels on TRT. Nevertheless, prospective randomized clinical trials are needed to ensure efficacy and security for this approach.

Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges. J Clin Neurosci Off J Neurosurg Soc Aust 22(10):1562–1567. https://doi.org/10.1016/j.jocn.2015.03.058CrossRef

Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107. https://doi.org/10.1210/jcem.82.7.4088CrossRefPubMed

Tirosh A, Benbassat C, Lifshitz A, Shimon I (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18(1):108–115. https://doi.org/10.1007/s11102-014-0563-zCrossRefPubMed

Behan LA, Draman MS, Moran C et al (2011) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 14(4):362–366. https://doi.org/10.1007/s11102-009-0168-0CrossRefPubMed

Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42–50. https://doi.org/10.1159/000495775CrossRefPubMed

Passos VQ, Fortes MAHZ, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89(2):163–170. https://doi.org/10.1159/000156116CrossRefPubMed

Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27–37. https://doi.org/10.1007/s11102-019-00987-3CrossRefPubMed

Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421–428. https://doi.org/10.1007/s11060-013-1270-8CrossRefPubMed

Sonigo C, Bouilly J, Carré N et al (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest 122(10):3791–3795. https://doi.org/10.1172/JCI63937CrossRefPubMedPubMedCentral

10.

Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704–1711. https://doi.org/10.1210/jc.2003-030979CrossRefPubMed

11.

Andereggen L, Frey J, Andres RH et al (2017) Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 97:595–602. https://doi.org/10.1016/j.wneu.2016.10.059CrossRefPubMed

12.

Mazziotti G, Porcelli T, Mormando M et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39(3):288–293. https://doi.org/10.1007/s12020-011-9462-5CrossRefPubMed

13.

Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87(10):4447–4451. https://doi.org/10.1210/jc.2002-020426CrossRefPubMed

14.

Bonert V (2020) Do nothing but observe microprolactinomas: when and how to replace sex hormones? Pituitary 23(3):307–313. https://doi.org/10.1007/s11102-020-01039-xCrossRefPubMed

15.

Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64(2):391–394. https://doi.org/10.1210/jcem-64-2-391CrossRefPubMed

16.

Sodi R, Fikri R, Diver M, Ranganath L, Vora J (2005) Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem 42(Pt 2):153–159. https://doi.org/10.1258/0004563053492784CrossRefPubMed

17.

Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. https://doi.org/10.1038/s41574-023-00886-5CrossRefPubMed

18.

Akirov A, Rudman Y (2023) The role of aromatase inhibitors in male prolactinoma. J Clin Med 12(4):1437. https://doi.org/10.3390/jcm12041437CrossRefPubMedPubMedCentral

19.

Carretero J, Burks DJ, Vázquez G et al (2002) Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats. Pituitary 5(1):5–10. https://doi.org/10.1023/a:1022176631922CrossRefPubMed

20.

García-Barrado MJ, Blanco EJ, Catalano-Iniesta L et al (2016) Relevance of pituitary aromatase and estradiol on the maintenance of the population of prolactin-positive cells in male mice. Steroids 111:121–126. https://doi.org/10.1016/j.steroids.2016.03.020CrossRefPubMed

21.

Akinci H, Kapucu A, Dar KA et al (2013) Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior. Pituitary 16(3):386–392. https://doi.org/10.1007/s11102-012-0436-2CrossRefPubMed

22.

Su YX, Du GL, Shen HL et al (2019) Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women. J Int Med Res 47(7):3115–3126. https://doi.org/10.1177/0300060519848916CrossRefPubMedPubMedCentral

23.

García Barrado MJ, Blanco EJ, Carretero Hernández M et al (2014) Local transformations of androgens into estradiol by aromatase P450 is involved in the regulation of prolactin and the proliferation of pituitary prolactin-positive cells. PLoS ONE 9(6):e101403. https://doi.org/10.1371/journal.pone.0101403CrossRefPubMedPubMedCentral

24.

Selek A, Halbutoğulları ZSU, Aydemir Çİ et al (2023) Letrozole decreased testosterone-induced cell proliferation and prolactin secretion also increased apoptosis in MMQ and GH3 rat prolactinoma cell lines. Mol Neurobiol 60(5):2442–2454. https://doi.org/10.1007/s12035-023-03220-2CrossRefPubMed

25.

Ceccato F, Lizzul L, Voltan G, Barbot M, Scaroni C (2021) Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary 24(6):914–921. https://doi.org/10.1007/s11102-021-01165-0CrossRefPubMedPubMedCentral

26.

Finkelstein JS, Whitcomb RW, O’Dea LS, Longcope C, Schoenfeld DA, Crowley WF (1991) Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73(3):609–620. https://doi.org/10.1210/jcem-73-3-609CrossRefPubMed

27.

Ribeiro RS, Abucham J (2009) Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 161(1):163–169. https://doi.org/10.1530/EJE-09-0084CrossRefPubMed

28.

Bell SG, Dalton L, McNeish BL et al (2020) Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol 159(2):509–514. https://doi.org/10.1016/j.ygyno.2020.08.015CrossRefPubMedPubMedCentral

29.

Rochira V, Kara E, Carani C (2015) The endocrine role of estrogens on human male skeleton. Int J Endocrinol 2015:165215. https://doi.org/10.1155/2015/165215CrossRefPubMedPubMedCentral

30.

Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet Lond Engl 365(9453):60–62. https://doi.org/10.1016/S0140-6736(04)17666-6CrossRef

31.

Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1–98 trial. Ann Oncol 20(9):1489–1498. https://doi.org/10.1093/annonc/mdp033CrossRefPubMedPubMedCentral

32.

Gennari L, Nuti R, Bilezikian JP (2004) Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 89(12):5898–5907. https://doi.org/10.1210/jc.2004-1717CrossRefPubMed

33.

Finkelstein JS, Lee H, Burnett-Bowie SAM et al (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369(11):1011–1022. https://doi.org/10.1056/NEJMoa1206168CrossRefPubMedPubMedCentral

34.

Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR (1999) Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 51(4):517–524. https://doi.org/10.1046/j.1365-2265.1999.00849.xCrossRefPubMed

35.

Nicoletti I, Filipponi P, Fedeli L, Ambrosi F, Gregorini G, Santeusanio F (1984) Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation. Acta Endocrinol (Copenh) 105(2):167–172. https://doi.org/10.1530/acta.0.1050167CrossRefPubMed

36.

Stumpf MAM, Pinheiro FMM, Silva GO et al (2023) How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26(2):187–196. https://doi.org/10.1007/s11102-023-01313-8CrossRefPubMed

37.

Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract 16(4):669–672. https://doi.org/10.4158/EP10026.CRCrossRefPubMed

Titel: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review
verfasst von: D. Zúñiga
M. A. M. Stumpf
A. L. S. Monteiro
A. Glezer
Publikationsdatum: 08.11.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 5/2024
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02231-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity

Choroidal vascularity index as a predictor for the development of retinopathy in diabetic patients

Reply to letter to editor “Knowledge gaps in diabetic striatopathy and other movement disorders in diabetes”

Correction: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review

Gastric GDF15 levels are regulated by age, sex, and nutritional status in rodents and humans